CONMED Corporation (NASDAQ:CNMD) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.86.
Shares of CONMED Corporation (NASDAQ CNMD) traded down 0.24% during mid-day trading on Friday, reaching $49.29. 89,869 shares of the company’s stock traded hands. The firm has a 50-day moving average of $50.36 and a 200 day moving average of $47.28. The company has a market cap of $1.38 billion, a P/E ratio of 88.18 and a beta of 0.67. CONMED Corporation has a 12-month low of $37.60 and a 12-month high of $52.82.
CONMED Corporation (NASDAQ:CNMD) last released its quarterly earnings data on Wednesday, July 26th. The medical technology company reported $0.41 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.41. The business had revenue of $197.20 million for the quarter, compared to the consensus estimate of $194.50 million. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.47 earnings per share. Equities analysts forecast that CONMED Corporation will post $1.87 EPS for the current year.
A number of equities research analysts recently weighed in on CNMD shares. BidaskClub downgraded shares of CONMED Corporation from a buy rating to a hold rating in a research note on Thursday, June 29th. Zacks Investment Research cut shares of CONMED Corporation from a hold rating to a sell rating in a research report on Tuesday, June 27th. Needham & Company LLC increased their price target on shares of CONMED Corporation from $54.00 to $57.00 and gave the company a buy rating in a research report on Thursday, July 27th. Ladenburg Thalmann Financial Services cut shares of CONMED Corporation from a buy rating to a neutral rating and reduced their price target for the company from $50.00 to $48.00 in a research report on Thursday, April 27th. Finally, TheStreet upgraded shares of CONMED Corporation from a c+ rating to a b- rating in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. CONMED Corporation currently has an average rating of Hold and an average target price of $49.33.
In other news, Director Dirk Kuyper sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $52.24, for a total value of $52,240.00. Following the transaction, the director now owns 10,739 shares in the company, valued at $561,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Jonas sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $51.22, for a total transaction of $153,660.00. Following the completion of the transaction, the executive vice president now owns 14,455 shares in the company, valued at approximately $740,385.10. The disclosure for this sale can be found here. 2.62% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “CONMED Corporation (CNMD) Releases FY17 Earnings Guidance” was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.baseball-news-blog.com/2017/08/14/conmed-corporation-cnmd-releases-fy17-earnings-guidance-2-updated-updated.html.
CONMED Corporation Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.